More than 4,000 actions alleging gastrointestinal injuries associated with GLP-1-based medicines are pending in a US federal multidistrict litigation (MDL). According to the latest statistics published by the US Judicial Panel on Multidistrict Litigation (JPML), 4,082 actions were pending in MDL No. 3094 as of 2 November 2026, while the total number of actions historically recorded in the MDL was 4,196. The litigation involves Novo Nordisk and Eli Lilly, whose medicines are the subject of claims alleging that their use caused serious gastrointestinal disorders and that manufacturers failed to provide...